Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFRα) gene expression in murine bone marrow cells
- 12 July 2002
- journal article
- Published by Elsevier BV in Life Sciences
- Vol. 71 (8), 967-978
- https://doi.org/10.1016/s0024-3205(02)01790-3
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- The Role of Antiretrovirals and Drug Resistance in Vertical Transmission of HIV‐1 InfectionAnnals of the New York Academy of Sciences, 2000
- Novel Approaches for Designing 5-O-Ester Prodrugs of 3-Azido-2,3-dideoxythymidine (AZT).Current Medicinal Chemistry, 2000
- Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Activity of 2′-fluoro-2′,3′-Dideoxyarabinosyladenine (F-ddA) Used in Combination with other Mechanistically Diverse Inhibitors of HIV-1 ReplicationAntiviral Chemistry and Chemotherapy, 1999
- A Randomized Comparative Trial of Stavudine (d4T) Versus Zidovudine (ZDV, AZT) in Children With Human Immunodeficiency Virus InfectionPEDIATRICS, 1998
- Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analysesAntiviral Research, 1997
- Side effects of AZT prophylaxis after occupational exposure to HIV-infected bloodAnnals of Hematology, 1994
- The Human Immunodeficiency Virus: Infectivity and Mechanisms of PathogenesisScience, 1988
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexThe New England Journal of Medicine, 1987
- Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.Proceedings of the National Academy of Sciences of the United States of America, 1986
- ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEXThe Lancet, 1986